07212009 Regular Meeting - Laserfiche WebLink

Home Browse Search

EXHIBIT "A" Business Description Grifols Inc., headquartered in Los Angeles, California, is the parent company of several subsidiaries whose vertically integrated operations involve collecting source blood plasma, processing the plasma through fractionation, and selling biopharmaceutical products throughout the world. The primary products are plasma volume expanders for shock and burn victims, coagulation products for hemophiliacs and intravenous immune globulins for auto-immune system disorders. In addition to its existing testing laboratory in Austin, and various plasma collection centers located throughout the state of Texas, Grifols desires to develop new locations pertaining to the above described business, including but limited to, the construction of laboratory, plasma processing, and warehouse facilities in San Marcos, Texas. Specifically, Grifols desires to, as Phase I of its expansion plan, develop a second testing laboratory in San Marcos to expand its operations, reduce the risk of business interruption with the availability of a second lab, and perform new required tests upon the collected plasma. At the new San Marcos Laboratory, samples from plasma collections will be tested by trained personnel using purchased test kits and specially designed computer programs. To expedite shipment, reduce transportation costs, and decrease risk of loss, Grifols desires to construct and maintain a warehouse in San Marcos as part of Phase II of the Project. This warehouse is intended to store production supplies and equipment, and will include freezers for the storage of frozen plasma in accordance with FDA regulations. The warehouse may also be used to store finished product for sale as well as business records. Grifols also intends to construct a second plasma fractionation plant in San Marcos. The plant will benefit Grifols' US operations by increasing production capacity, reducing business interruption risk, and decreasing overseas shipping costs. The primary activity to be performed at this plant will be the extraction of plasma pastes and proteins through filtration and centrifugation processes. The construction of such second plasma fractionation plant shall be included within Phase II of the Project or may be considered as Phase III. Page 18 of 22